The Latest Breaking News on Pharma

Biotech Bulls: 3 Stocks With Buying Potential

The biotech industry's upward trajectory is being fueled by the advancement of orphan medications, innovative biotech equipment, personalized medicine, and robust government support. Thus, biotech stocks ANI Pharmaceuticals (ANIP), Equillium (EQ), and Exelixis (EXEL) might serve as ideal additions to your portfolio. Read more….

StockNews.com · Jan 30, 2024

Pharma Buy, Hold, or Sell: 4 Stocks Worth Considering

The pharmaceutical industry is anticipated to thrive as demand grows and technology advances. However, given the macroeconomic uncertainties, let us analyze leading pharma stocks Zoetis (ZTS), Verano Holding (VRNOF), Canopy Growth (CGC) and SNDL (SNDL) to identify whether they are a Buy, Hold, or Sell. Read on.

StockNews.com · Jan 30, 2024

4 Biotech Stocks With Massive Buy Potential

The biotech sector is poised for robust long-term growth, driven by significant developments in drug approvals, innovative therapies, and government-backed initiatives. Hence, investors might consider buying fundamentally solid biotech stocks ProQR Therapeutics (PRQR), Foghorn Therapeutics (FHTX), Harmony Biosciences (HRMY), and Organogenesis Holdings (ORGO) with massive buy potential. Keep reading.

StockNews.com · Jan 30, 2024

More than 10,000 spared GP visit under new trials

A series of trials operating across the nation has allowed 10,000 women to get a new supply of the pill or receive treatment for uncomplicated infections.

AAP · Jan 23, 2024

Johnson & Johnson (JNJ): Analyzing Signals Before Quarterly Earnings

Pharmaceutical powerhouse Johnson & Johnson (JNJ) is proactively driving innovation throughout the healthcare spectrum, thanks to its strong focus on innovative medicines and MedTech solutions. However, with the company’s fiscal fourth-quarter earnings on the horizon, could the stock be a wise portfolio addition? Keep reading to find out….

StockNews.com · Jan 22, 2024

NHS drug shortages are partly a political failure

Letters: Britain is pushing for patent changes in India that could increase the cost of generic drugs, writes Tim Bierley; plus letters from readers on the human cost of shortages

The Guardian - UK · Jan 22, 2024

3 Pharma Stocks to Watch in 2024 for Later Gains

The pharmaceutical industry looks well-positioned for long-term growth. Hence, pharma stocks Procaps Group (PROC), Organon (OGN) and Amphastar (AMPH) might be ideal additions to your watchlists for later gains. Read on.

StockNews.com · Jan 19, 2024

What’s the Best 2024 Pharma Stock Buy Among These 3 Stocks?

The pharma industry's potential for sustained growth is reinforced by an aging population, escalating healthcare demands, and the increase in chronic diseases. Therefore, let’s assess the fundamentals of pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Abbvie (ABBV) to determine the most promising choice for the current year….

StockNews.com · Jan 18, 2024

2024 Will Be a Good Year for the Pharma Industry: The Kiplinger Letter

Five pharma companies will have sales that exceed $50 billion this year.

Kiplinger · Jan 18, 2024

Generic drugs in the US are too cheap to be sustainable, experts say

Non-brand-name drugs are one inexpensive part of the healthcare system but they’re driving some manufacturers out of business

The Guardian - US · Jan 18, 2024